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Abstract
Rationale Aberrant glutamatergic, dopaminergic, and GABAergic neurotransmission has been implicated in schizophrenia.
Cariprazine reverses the behavioral effects observed in the rat phencyclidine (PCP)-induced model of schizophrenia; however,
little is known about its in vivo neurochemistry.
Objectives The study aims to compare the effects of cariprazine and aripiprazole on PCP-induced changes in the extracellular
levels of glutamate, dopamine, serotonin, noradrenaline, and GABA in the rat medial prefrontal cortex (mPFC), and on loco-
motor activation.
Methods Microdialysis was performed in awake rats with probes placed into the mPFC. Rats (n = 7/group) received vehicle
(saline), cariprazine (0.05, 0.2, or 0.8 mg/kg), or aripiprazole (3 or 20 mg/kg) via gavage. After 60 min, 5 mg/kg PCP was
administered intraperitoneally (i.p.). Samples were taken before drug administration, during pretreatment, and after PCP injec-
tion. Locomotor activity recording and microdialysis sampling occurred simultaneously.
Results PCP treatment increased extracellular levels of all the neurotransmitters tested except GABA, for which there were no
significant changes. Cariprazine and aripiprazole dose-dependently inhibited the PCP-induced increases of tested neurotransmit-
ters. Overall effects were significant for higher cariprazine doses and both aripiprazole doses for glutamate and noradrenaline, for
higher cariprazine doses and 20 mg/kg aripiprazole for dopamine, and for 0.8 mg/kg cariprazine and 20 mg/kg aripiprazole for
serotonin and locomotor activity.
Conclusion Both cariprazine and aripiprazole dose-dependently attenuated PCP-induced hyperlocomotion and acute increases in
glutamate, dopamine, noradrenaline, and serotonin levels in the mPFC; cariprazine was approximately 5-fold more potent than
aripiprazole.
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Introduction
Schizophrenia is a debilitating, lifelong psychiatric disorder
affecting approximately 1% of the population. Currently used
antipsychotics are effective in improving positive symptoms
but have relatively little benefit on the negative symptoms
(e.g., social withdrawal and anhedonia) and cognitive deficits
(Millan et al. 2016). Cariprazine (Vraylar™), a potent dopa-
mine (DA) D3 and D2 receptor partial agonist with preferential
binding to D3 receptors and partial agonism at serotonin 5-
HT1A receptors (Kiss et al. 2010), has recently been approved
in the USA for the treatment of schizophrenia and bipolar
mania in adults. It is also currently in clinical development
for the treatment of bipolar depression and adjunctive treat-
ment of major depressive disorder.
The D3 receptor is thought to play a role in mood and
cognition, and it has recently emerged as a potential pharma-
cological target for neuropsychiatric disorders (Gross and
Drescher 2012; Sokoloff et al. 2006). Cariprazine was devel-
oped based on the hypothesis that high affinity at D3 and D2
receptors may result in potent antipsychotic efficacy through
D2 receptor blockade and confer additional D3 receptor-
mediated benefits in the treatment of affective and cognitive
deficits associated with schizophrenia and bipolar disorder
(Gyertyán et al. 2008; Kiss et al. 2008). Cariprazine differs
from currently used atypical antipsychotics (Ellenbroek and
Cesura 2014) by having higher in vitro affinity and selectivity
(almost an order of magnitude) for D3 versus D2 receptors
(Kiss et al. 2010) and high levels of in vivo occupancy of both
D3 and D2 receptors at antipsychotic-like effective doses in
rats (Gyertyán et al. 2011) and clinically active dose ranges in
patients with schizophrenia (Girgis et al. 2016). Other atypical
antipsychotics, such as aripiprazole, clozapine, olanzapine,
and risperidone, did not show significant D3 receptor occu-
pancy at antipsychotic-like doses in rats (Kiss et al. 2012) or
clinically relevant doses in patients (Caravaggio et al. 2014;
Graff-Guerrero et al. 2009; Mizrahi et al. 2011). These data
indicate that cariprazine can modulate in vivo D3 receptor
activity to a greater extent than other antipsychotics.
Dysregulation in the glutamatergic, dopaminergic, and
GABAergic neurotransmission systems may underlie the
pathophysiological changes in the brain that lead to schizo-
phrenia (Abi-Dargham et al. 2012; Kristiansen et al. 2006;
Laruelle et al. 1996; Stan and Lewis 2012). NMDA receptor
antagonists such as phencyclidine (PCP) induce psychopa-
thology resembling the symptoms of schizophrenia in healthy
individuals (Luby et al. 1959) and exacerbate schizophrenia
symptoms in patients (Malhotra et al. 1997). PCP-based
models have, therefore, routinely been used to model schizo-
phrenia symptoms in animals (Javitt 1987; Neill et al. 2014;
Sams-Dodd 1999). PCP is believed to produce adverse behav-
ioral effects via blockade of the NMDA receptors on the
GABAergic interneurons in the medial prefrontal cortex
(mPFC) (Yonezawa et al. 1998), disinhibiting the cortico-
cortical glutamatergic neurons (Berendse et al. 1992;
Fonnum et al. 1981) and leading to increased glutamate
(Glu) levels in the mPFC (Adams and Moghaddam 1998;
Krystal et al. 2003; Moghaddam and Adams 1998). In addi-
tion to its effects on Glu efflux, PCP increases DA and sero-
tonin (5-HT) release in the PFC (Hondo et al. 1994; Martin
et al. 1998; Verma and Moghaddam 1996). Dysregulation of
these monoamine neurotransmitter systems has also been im-
plicated in schizophrenia (Carlsson 1978; Howes et al. 2015;
Meltzer 1989).
We have previously demonstrated that in animal models of
schizophrenia, cariprazine reversed PCP-induced behavioral
effects (hyperlocomotion) (Gyertyán et al. 2011), demonstrat-
ing putative efficacy against positive symptoms of schizophre-
nia. In the follow-up study in mice, cariprazine significantly
diminished the PCP-induced cognitive deficits in wild-type
but not in D3 receptor knockout mice (Zimnisky et al. 2013).
In addition, two recent studies provide further support for the
ability of cariprazine to ameliorate cognitive and social defi-
cits induced by PCP in adult rats (Neill et al. 2016) and in a
PCP neurodevelopmental model of schizophrenia in rats
(Watson et al. 2016). Together, the results from the PCP
models of schizophrenia suggest that cariprazine may exert
beneficial effects on the cognitive and social/affective func-
tions disrupted by PCP, at least in part via its high affinity to
the D3 receptors. Cariprazine displays subnanomolar affinity
for the human D3 receptors, with approximately 5–10-fold
selectivity over D2L, D2S, 5-HT1A, and 5-HT2B receptor sub-
types. It displayed much lower affinity for the adrenergic
(α1A, α1B, α1D, α2A, β1, β2), 5-HT2A, histamine H1, 5-HT7,
and 5-HT2C receptors (Kiss et al. 2010). Using in vitro func-
tional assays, cariprazine has shown an antagonist profile in G
protein recruitment, and partial agonism in cAMP and β-
arrestin signaling (Gao et al. 2015; Kiss et al. 2010). This
unique receptor profile may account for the therapeutic effi-
cacy of cariprazine. Indeed, cariprazine demonstrated en-
hanced efficacy for treating negative symptoms, compared
with risperidone, in patients with predominant negative symp-
toms (Németh et al. 2017) and demonstrated efficacy versus
placebo in patients with acute exacerbation of schizophrenia
(Durgam et al. 2015; Durgam et al. 2014; Kane et al. 2015).
Moreover, cariprazine has demonstrated efficacy in patients
with bipolar depression and as adjunctive treatment in patients
with major depressive disorder (Durgam et al. 2016a; Durgam
et al. 2016b).
Considering the proven predictive validity of cariprazine in
behavioral PCP models, it was of interest to examine to what
extent cariprazine maymodulate the PCP-induced increases in
extracellular levels of the neurotransmitters Glu, DA, nor-
adrenaline (NA), and 5-HT. There is little information on the
in vivo neurochemistry of cariprazine. In the report of Kiss
et al. (2010), cariprazine moderately increased DA turnover
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and slightly reduced 5-HT turnover in the mouse striatum,
olfactory tubercles, and frontal cortex. Both cariprazine and
aripiprazole, unlike risperidone, olanzapine, or haloperidol,
produced greater enhancement of DA turnover and biosynthe-
sis in the mouse limbic regions (olfactory tubercle) than in the
striatum (Kiss et al. 2010). While these findings are indicative
of the low propensity of cariprazine to induce extrapyramidal
side effects, they do not predict the impact of cariprazine on
neurotransmitter release and metabolism in the rodent model
of schizophrenia.
The purposes of the present study were (1) to test the ability
of cariprazine to modulate PCP-induced changes in the extra-
cellular levels of neurotransmitters, including Glu, GABA,
and the monoamines DA, NA, and 5-HT, as measured by
microdialysis in the rat mPFC, while simultaneously record-
ing their locomotor activity as a behavioral measure of
antipsychotic-like effects and (2) to compare the effects of
cariprazine on these endpoints to aripiprazole, a DA receptor
partial agonist antipsychotic with higher affinity to D2 than to
D3 receptors both in vivo and in vitro (Gyertyán et al. 2011;
Kiss et al. 2010).
Materials and methods
Animals
Male Sprague Dawley rats (8–10 weeks of age, weighing
300–350 g at the day of experiment) were used in the study.
The rats were received at approximately 200–250 g from
Janvier Labs, France. Animals were allowed a minimum ac-
climatization period of 1 week prior to performing any exper-
iments. No prophylactic or therapeutic treatment was admin-
istered during the acclimatization period. Animals were main-
tained in a controlled environment (22 ± 1 °C; 45–50% rela-
tive humidity) on a 12-h dark/12-h light (40 lx, lights on at
7:00 am) cycle. Room temperature and humidity were record-
ed continuously in the holding room. All rats were examined
and weighed prior to initiation of the study to assure adequate
health and suitability. Rats were randomly assigned to treat-
ment groups.
All animal experiments and protocols were approved by
the regional ethical committee at Stockholm County Court
(Stockholms Norra djurförsöksetiska nämnd) following the
directives of the Swedish Animal Welfare Act 1988:534 and
complying with the Directive 2010/63/EU (Council of the
European Parliament) BThe Guide for the Care and Use of
Laboratory Animals^ and the BPrinciples of Laboratory
Animal Care^ (NIH Publications no. 85-23). All efforts were
made to minimize animal suffering and the number of animals
used for the study. The results are reported in accordance with
the ARRIVE guidelines for reporting experiments involving
animals (McGrath et al. 2010).
Test compounds
Cariprazine hydrochloride salt and aripiprazole free base were
provided by the Forest Research Institute, NJ, USA. PCP hy-
drochloride salt was purchased from LGC Standards (Boras,
Sweden). All compounds were dissolved in saline on the day
of the experiment.
Groups and doses
Microdialysis experiments were carried out on six groups of
seven rats each. Cariprazine and aripiprazole were adminis-
tered orally (p.o.) to separate groups of rats; PCP was injected
intraperitoneally (i.p.). Rats were treated with vehicle (saline,
p.o.), cariprazine (0.05, 0.2, or 0.8 mg/kg, p.o.), or
aripiprazole (3 or 20 mg/kg, p.o.). These doses of cariprazine
have demonstrated an antipsychotic-like efficacy in a PCP-
induced behavioral model (Gyertyán et al. 2011). As
cariprazine was shown to be 5–20 times more potent than
aripiprazole in behavioral tests, doses of 3 and 20 mg/kg were
used in the present study. Sixty minutes after the p.o. admin-
istration, all groups received PCP (5 mg/kg, i.p.). All doses
were calculated as a free base.
Experimental procedures
Microdialysis
The microdialysis experiments were carried out on awake rats
following the protocol described elsewhere (Kehr 1999; Kehr
and Yoshitake 2006; Osborne et al. 1990).
Surgery and microdialysis experiments
Initially, the rats were anesthetized with isoflurane using a
Univentor 400 anesthesia unit (AgnTho’s, Lidingö, Sweden)
and placed in a stereotaxic frame (David Kopf Instruments,
Tujunga, CA, USA) using a flat skull position with the incisor
bar set to − 3.2 mm. During the operation, the body tempera-
ture of the animal was controlled by a thermometer and a
heating pad maintained at 37 °C by the use of a CMA/150
temperature controller (CMA Microdialysis, Stockholm,
Sweden). A middle scalp incision of 2–3 cm was made, and
the flaps were held open using homeostatic forceps. After
exposing the skull, a hole for the implantation of the guide
cannula and three holes for the anchor screws were drilled
using a fine trephine drill. Threemicroscrews were placed into
the skull. A guide cannula (EICOM, Kyoto, Japan) was im-
planted into the mPFC at the following coordinates: AP +
3.2 mm, L + 0.5 mm, and V − 1.2 mm from the bregma and
the brain surface, using the stereotaxic atlas of Paxinos and
Watson (2007). The guide cannula was fixed firmly to the
skull surface using dental cement (Dentalon Plus, Heraeus,
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Germany). The animals were allowed to recover for 5–7 days,
kept individually in their home cages (Eurostandard type III
H, Tecniplast, Italy) while maintaining visual, vocalization,
and olfactory contact. During this period, the body weight
and the general status of the animals were monitored on a
regular basis.
On the day of the experiment, a microdialysis probe
(EICOM A-I: 0.22 mm OD, 3 mm membrane length with
50 kDa cutoff) was inserted into the guide cannulae of the
awake rat. The rat was placed into the system for freely
moving animals (EICOM) equipped with a two-channel
swivel (TCS2-23; ALS, Tokyo, Japan). The probes were
perfused at a constant flow rate of 1 μl/min with artificial
cerebrospinal fluid solution (148 mM NaCl, 4 mM KCl,
0.8 mM MgCl2, 1.4 mM CaCl2, 1.2 mM Na2HPO4,
0.3 mM NaH2PO4, pH 7.2). Following a 120-min stabili-
zation period, the samples were collected every 30 min.
Fifteen microliters of 0.1 M phosphate buffer (pH 3.0)
containing 0.1 mM EDTA-2Na was pipetted into each
300-μl polypropylene sample vial placed in the refriger-
ated microfraction collector (EICOM). The first three
30-μl samples (collected from − 150 to − 60 min) were
taken to measure the basal extracellular levels of Glu,
GABA, DA, NA, and 5-HT. Thereafter, the drug or saline
was administered p.o., and two samples were collected
during an additional 60 min (− 60 to 0 min). At time
0 min, PCP (5 mg/kg, i.p.) was administered, and samples
were collected for additional 3 h. After finalizing the ex-
periment, the probe was removed. A microdialysis probe
with its membrane removed acted as an infusion needle
and was then inserted into the guide cannula. The infusion
cannula was connected to a 10-μl Hamilton syringe with
2% aqueous solution of Evans blue dye, and 0.1 μl was
infused into the brain by the use of a CMA/100 microin-
jection pump. The animals were sacrificed by an overdose
of isoflurane and cervical dislocation. The brains were
removed, fixed in 4% formalin in phosphate-buffered sa-
line for 3–5 days, and cut in 60-μm sections for histolog-
ical verification of the microdialysis probe placement.
Locomotor activity test
Locomotor activity was monitored by the use of a single-beam
activity frame (44 × 30 cm ACTIMO 10, Shintechno, Japan)
placed around the lower part of the Eurostandard type III cage.
This arrangement allowed for simultaneous recordings of lo-
comotor activity and microdialysis sampling. The data were
collected by counting and summarizing the overall activity
(number of beam crossings) in 5-min intervals and were fur-
ther pooled in each respective 180-min sampling period,
thereby corresponding to the microdialysis data expressed as
the relative area under the curve (AUC(0–180 min)) values.
HPLC analysis
Glutamate and GABA Amino acid neurotransmitters Glu and
GABA were determined by precolumn derivatization with
ortho-phthalaldehyde (OPA)/mercaptoethanol and isocratic
elution reversed-phase column liquid chromatography with
fluorescence detection following a minor modification of the
protocol described elsewhere (Kehr 1998, 1999; Kehr and
Yoshitake 2006). Briefly, the amino acid analyzer included a
LC-10AD pump (Shimadzu, Kyoto, Japan), a LC-27A
degasser (ALS, Tokyo, Japan), a CMA/200 refrigerated
microsampler equipped with a 20-μl loop and operating at
6 °C, a L-7480 fluorescence detector (Hitachi, Tokyo,
Japan), and the Clarity Data Acquisition System (DataApex,
Prague, The Czech Republic). The analytical column was a
150 × 3.0 mm Eicompak SC-5ODS column (EICOM, Kyoto,
Japan). The mobile phase was a mixture (34:66, v/v) of meth-
anol and 0.1 M phosphate buffer (pH 6.0). The flow rate was
0.335 ml/min. The OPA/mercaptoethanol derivatization re-
agent was prepared daily from the OPA stock solution.
Automated derivatization was carried out in the CMA/200
autosampler by dispensing and mixing the aliquot volumes
of the sample and the reagent. Following the reaction time
of 250 s, 10 μl was injected onto the column. The detection
limit (signal-to-noise ratio = 3) for Glu andGABAwas 10 fmol
in the 10 μl injected onto the column.
DA, NA, and 5-HT Monoamines 5-HT, NA, and DAwere de-
termined by ion-exchange narrow-bore column liquid chro-
matography with electrochemical detection as described else-
where (Kehr 1999; Yoshitake et al. 2014). The chromato-
graphic conditions were optimized to allow simultaneous de-
termination of all three monoamines in the same sample.
Briefly, a HPLC system, with an electrochemical detector
(EICOM, Kyoto, Japan), and a CMA/200 refrigerated
microsampler (CMA Microdialysis), equipped with a 20-μl
loop and operating at 6 °C, were used. The electrochemical
detector was equipped with a radial-flow electrochemical cell
(EICOM) with the glassy carbon working electrode operating
at the potential of + 450 mV versus the Ag/AgCl reference
electrode. Monoamines were separated on a 200 × 2.0 mm ID
column (CAX, EICOM). The mobile phase consisted of
0.1 M phosphate buffer at pH 6.0, 40 mM potassium chloride,
0.13 mM EDTA-2Na, and 30% (v/v) methanol. Under these
conditions, the detection limits (signal-to-noise ratio = 3) for
DA, NA, and 5-HT were 0.5, 0.6, and 0.5 fmol, respectively,
in the 15 μl injected onto the column.
Data presentation and analysis
Statistical analysis was performed using Prism 6
(GraphPad Software, USA) statistical software. The
values are presented as means ± standard error of the
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mean (SEM), and differences are considered to be statis-
tically significant at the P < 0.05 level. The basal extra-
cellular levels were calculated and expressed as
means ± SEM from seven rats in each group; the value
for each rat in the respective group was calculated as the
mean of three fractions collected from the − 120- to − 60-
min period. For graphic representation of neurotransmitter
outflow over time, the data were expressed as the percent-
age of the basal concentrations at time 0 min. The overall
effects of the drug and vehicle treatments were expressed
as the relative AUC value, defined here as the percentage
of baseline values averaged over the 180-min post-treat-
ment sampling period (rel. AUC(0–180 min)). Mean basal
levels of the control and treatment groups were compared
by using the Kruskal-Wallis test followed by Dunn’s mul-
tiple comparison test. Differences between the groups and
treatments were analyzed by repeated measures two-way
ANOVA followed by Bonferroni’s post test. Differences
between the AUC(0–180 min) values were compared by
one-way ANOVA followed by Dunnett’s multiple com-
parison test.
Results
Probe placement in the mPFC
Histological verification of the microdialysis probe placement
in rat brain sections revealed that the microdialysis probe
membranes were placed exclusively in the mPFC, including
cingulate, prelimbic, and infralimbic cortices.
Basal extracellular levels of Glu, GABA, DA, NA,
and 5-HT
The basal extracellular levels of Glu, GABA, DA, NA,
and 5-HT in the rat mPFC in the saline-, cariprazine-,
and aripiprazole-treated groups are summarized in
Table 1. There were no significant differences between
the mean basal levels of Glu, GABA, DA, NA, and 5-
HT between the treated groups, with the exception of 5-
HT, where the basal levels of the groups treated with
cariprazine at 0.2 and 0.8 mg/kg were significantly lower
(P < 0.05) than those of the control group. This could be
partially explained by the variations in batches of the mi-
crodialysis probes, which could have lower recovery for
these groups. In addition, the variations in estimated basal
5-HT levels could be caused by variations in chromato-
graphic calibrations of 5-HT, which is the last eluting
peak (16.2 min) in the chromatogram, and low (1–
2 fmol/10 μl) concentrations of 5-HT are close to the limit
of detection of the HPLC method. Other contributing fac-
tors, such as minor differences in animal experimental Ta
bl
e
1
B
as
al
ex
tr
ac
el
lu
la
rl
ev
el
s
of
G
lu
,G
A
B
A
,D
A
,N
A
,a
nd
5-
H
T
in
th
e
ra
tm
PF
C
in
th
e
sa
lin
e-
,c
ar
ip
ra
zi
ne
-,
an
d
ar
ip
ip
ra
zo
le
-t
re
at
ed
gr
ou
ps
ca
lc
ul
at
ed
fr
om
th
e
fi
rs
tt
hr
ee
sa
m
pl
es
(c
ol
le
ct
ed
fr
om
−
15
0
to
−
60
m
in
)
an
d
ex
pr
es
se
d
as
m
ea
n
±
SE
M
va
lu
es
,u
si
ng
th
e
K
ru
sk
al
-W
al
lis
te
st
fo
llo
w
ed
by
D
un
n’
s
m
ul
tip
le
co
m
pa
ri
so
n
te
st
S
al
in
e
+
sa
lin
e
C
ar
ip
ra
zi
ne
0.
2
m
g/
kg
+
sa
lin
e
S
al
in
e
+
P
C
P
C
ar
ip
ra
zi
ne
0.
05
m
g/
kg
+
PC
P
C
ar
ip
ra
zi
ne
0.
2
m
g/
kg
+
PC
P
C
ar
ip
ra
zi
ne
0.
8
m
g/
kg
+
P
C
P
A
ri
pi
pr
az
ol
e
3
m
g/
kg
+
P
C
P
A
ri
pi
pr
az
ol
e
20
m
g/
kg
+
P
C
P
G
lu
(p
m
ol
/1
0
μ
l)
7.
21
±
1.
67
6.
72
±
1.
41
5.
01
±
0.
91
5.
08
±
0.
62
10
.0
6
±
1.
18
5.
94
±
0.
99
5.
40
±
0.
69
8.
76
±
2.
42
G
A
B
A
(f
m
ol
/1
0
μ
l)
22
7
±
24
.9
28
7
±
42
.1
25
7
±
93
.3
22
3
±
50
.0
19
3
±
57
.9
20
3
±
44
.7
20
5
±
72
.3
23
7
±
51
.3
2
D
A
(f
m
ol
/1
0
μ
l)
2.
58
±
0.
27
8
2.
93
±
0.
30
3
3.
95
±
0.
38
6
3.
72
±
0.
69
7
5.
70
±
1.
42
3
2.
53
±
0.
60
1
3.
72
±
0.
96
9
3.
71
±
0.
46
1
N
A
(f
m
ol
/1
0
μ
l)
8.
13
±
0.
65
5
8.
04
±
0.
75
4
8.
31
±
0.
93
0
8.
22
±
1.
02
8.
79
±
1.
27
7.
97
±
0.
99
3
8.
00
±
0.
89
2
8.
32
±
0.
34
7
5-
H
T
(f
m
ol
/1
0
μ
l)
2.
24
±
0.
22
7
2.
93
±
0.
49
8
2.
38
±
0.
24
9
1.
38
±
0.
06
5
1.
24
±
0.
11
8*
1.
23
±
0.
09
4*
1.
42
±
0.
16
7
1.
44
±
0.
13
8
5-
H
T
se
ro
to
ni
n,
D
A
do
pa
m
in
e,
G
A
B
A
ga
m
m
a-
am
in
ob
ut
yr
ic
ac
id
,G
lu
gl
ut
am
at
e,
N
A
no
ra
dr
en
al
in
e
*P
<
0.
05
co
m
pa
re
d
to
th
e
sa
lin
e
+
sa
lin
e
gr
ou
p
Psychopharmacology (2018) 235:1593–1607 1597
conditions, including the stabilization period after the
probe insertion, between the tested groups, could not be
excluded.
Effects of cariprazine and aripiprazole on PCP-induced
increase in extracellular levels of Glu and GABA
Administration of PCP (5 mg/kg, i.p.) at time 0 min caused a
rapid and significant (P < 0.05) increase in extracellular Glu
levels already in the first 30-min samples and reached the
maximal value of 191 ± 30% at 120 min as compared to the
control (saline + saline)-treated group (Fig. 1a). Pretreatment
with cariprazine 60 min before PCP administration signifi-
cantly attenuated the PCP-inducedGlu release starting already
at 30 min after the PCP injection when cariprazine was given
at doses of 0.2 mg/kg (P < 0.05) and 0.8 mg/kg (P < 0.01), but
not at 0.05 mg/kg. Notably, cariprazine (0.2 mg/kg + saline)
administered alone had no effect on basal Glu levels. The
results of the statistical analysis using two-way repeated mea-
sures ANOVA followed by Bonferroni’s post test are summa-
rized in Table 2. The analysis (F and P values) revealed the
significant effects of interaction time and treatment, treatment,
and time. Similarly, pretreatment with aripiprazole at both
tested doses significantly (P < 0.05 for 3 mg/kg and
P < 0.01 for 20 mg/kg) attenuated the PCP-induced Glu re-
lease starting at 30 and 60 min after PCP injection, respective-
ly, as shown in Fig. 1b and summarized in Table 2.
The overall effects of cariprazine and aripiprazole on the
attenuation of the PCP-induced increase in Glu levels
(expressed as the relative AUC(0–180 min) values of the drug-
treated groups and compared to the saline + PCP group) are
shown in Fig. 2a. One-way ANOVA followed by Dunnett’s
multiple comparison test revealed that the relative AUC(0–
180 min) values were significantly lower (P < 0.001) for the
saline + saline-treated group and cariprazine 0.2 mg/kg +
saline-treated group when compared to the saline + PCP-
treated group. Likewise, there were significant differences in
the AUC(0–180 min) values of Glu between the groups treated
with 0.2 and 0.8 mg/kg cariprazine (P < 0.001 for both doses)
and 20 mg/kg (P < 0.001) aripiprazole as compared to the
saline + PCP-treated group. As both doses of cariprazine
caused approximately the same effect, i.e., the Glu levels in
these groups were not significantly different from the levels in
the control group (Fig. 2a), it could be concluded that the
intermediate (0.2 mg/kg) dose of cariprazine was sufficient
to elicit the maximal effect on the attenuation of the PCP-
induced increase in extracellular Glu levels in the rat mPFC.
Administration of PCP at time 0 min had no significant
impact on the extracellular GABA levels. There was only a
tendency towards decreased values; the lowest level, 79 ± 8%
of the controls, was achieved at 120 min (Supplementary
Figure 1A). Pretreatment with cariprazine or aripiprazole
Fig. 1 Effects of a cariprazine and b aripiprazole on the PCP-induced
increase in extracellular levels of Glu in the mPFC of awake rats. a PCP
significantly increased the Glu levels as compared to the saline + saline-
treated group (hexagons; ★, P < 0.05; ★★, P < 0.01; ★★★, P < 0.001)
and cariprazine 0.2 mg/kg + saline-treated group (triangles down; ,
P < 0.05; , P < 0.01; , P < 0.001). Cariprazine
significantly attenuated the PCP-induced Glu efflux at 0.2 mg/kg
(triangles up; ✠, P < 0.05; ✠✠✠, P < 0.001) and 0.8 mg/kg (diamonds;
✚✚, P < 0.01; ✚✚✚, P < 0.001), but not at 0.05 mg/kg (squares). b The
significant PCP-induced increase in Glu levels (★, P < 0.05; ★★,
P < 0.01; ★★★, P < 0.001) was significantly attenuated by
aripiprazole at both 3 mg/kg (triangles; , P < 0.05; , P < 0.01;
, P < 0.001) and 20 mg/kg (diamonds; ✞✞✞, P < 0.001) starting
60 min after the PCP injection
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resulted in no significant differences between the treated
groups (Table 2; Supplementary Figure 1B).
Effects of cariprazine and aripiprazole on PCP-induced
increases in extracellular levels of DA, NA, and 5-HT
Administration of PCP at time 0min caused a rapid increase in
extracellular DA levels at 30 min (P < 0.001) and reached the
maximal value of 363 ± 14% of the control DA levels at
60 min (Fig. 3a). Pretreatment with cariprazine at all three
doses significantly (P < 0.001) attenuated the PCP-induced
DA release starting at 30 min after the PCP injection.
Similarly, pretreatment with aripiprazole significantly
(P < 0.001, both for 3 and 20 mg/kg) attenuated the PCP-
induced DA release starting at 30 min after the PCP injection
(Fig. 3b). The results of statistical analysis with the corre-
sponding F and P values are listed in Table 2. The DA levels
in a separate group treated with cariprazine 0.2 mg/kg + saline
were not different from the levels of the control group,
confirming that cariprazine alone had no effect on the basal
DA levels in the rat mPFC. The overall effects of cariprazine
and aripiprazole on the attenuation of the PCP-induced in-
crease in DA levels, expressed as the relative AUC(0–180 min)
values of the drug-treated groups and compared to the saline +
PCP group, are shown in Fig. 3c. There were significant dif-
ferences in the AUC(0–180 min) values of DA between the
groups treated with cariprazine at 0.05 mg/kg (P < 0.05), at
0.2 and 0.8 mg/kg (P < 0.001 for both), as well as for the
group treated with 20 mg/kg aripiprazole (P < 0.001) as com-
pared to the saline + PCP-treated group. The two higher doses
of cariprazine caused similar effects.
PCP also markedly and significantly (P < 0.001) increased
the extracellular levels of NA already in the first 30-min frac-
tion and reached the maximal value of 337 ± 13% of the
control levels at 60 min. Pretreatment with cariprazine signif-
icantly (P < 0.001) attenuated the PCP-induced NA release,
starting with the first fraction collected at 30 min after the PCP
injection (Fig. 4a). Cariprazine was effective at all three doses
tested, whereas cariprazine (0.2 mg/kg) administered alone
had no effects on the basal NA levels.
Likewise, pretreatment with aripiprazole at both tested
doses significantly (P < 0.001) attenuated the PCP-induced
NA release, starting at 30 min after the PCP injection
(Fig. 4b). The statistical analysis results and the corresponding
F and P values are listed in Table 2. The overall effects of
cariprazine and aripiprazole on the attenuation of the PCP-
Table 2 Two-way repeated measures ANOVA followed by Bonferroni’s multiple comparison test for the values of Glu, GABA, DA, NA, and 5-HT
and the locomotor activity
Time × treatment Treatment Time
Microdialysis data (time course, % of control)
F(50,300) P F(5,30) P F(10,300) P
Cariprazine
Glu 3.682 < 0.0001 8.175 < 0.0001 11.88 < 0.0001
GABA 1.142 n.s. 0.693 n.s. 0.453 n.s.
DA 6.226 < 0.0001 11.82 < 0.001 26.85 < 0.0001
NA 8.734 < 0.0001 13.25 < 0.0001 32.62 < 0.0001
5-HT 2.774 < 0.0001 4.557 < 0.01 10.06 < 0.0001
F(30,210) P F(3,21) P F(10,210) P
Aripiprazole
Glu 4.045 0.0001 8.297 0.001 5.976 0.0001
GABA 1.183 n.s. 1.142 n.s. 0.725 n.s.
DA 7.049 0.0001 18.85 0.0001 23.62 0.0001
NA 7.835 0.0001 12.54 0.001 33.52 0.0001
5-HT 2.261 0.001 8.289 0.001 5.89 0.0001
Locomotor activity (time course, counts/5 min)
F(325,1950) P F(5,30) P F(65,1950) P
Cariprazine 1.728 < 0.0001 5.643 < 0.001 4.608 < 0.0001
F(195,1365) P F(3,21) P F(65,1365) P
Aripiprazole 2.627 < 0.0001 4.683 < 0.02 5.027 < 0.0001
The groups were pretreated with cariprazine or aripiprazole, followed by PCP treatment, and compared to the saline + PCP-treated group. The
microdialysis data were calculated as the relative values expressed as the percentage of the basal levels at time 0 min for each respective group; the
locomotor activity was counted in 5-min bins (not significant (n.s.), P > 0.05)
5-HT serotonin, DA dopamine, GABA gamma-aminobutyric acid, Glu glutamate, NA noradrenaline
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induced increase in NA levels, expressed as the relative
AUC(0–180 min) values of the drug-treated groups and com-
pared to the saline + PCP group, are shown in Fig. 5c. The
AUC(0–180 min) values were significantly lower for the groups
treated with 0.05 mg/kg (P < 0.05), 0.2 mg/kg (P < 0.001),
and 0.8 mg/kg (P < 0.001) cariprazine, similar to the groups
treated with aripiprazole at 3 mg/kg (P < 0.05) and 20 mg/kg
(P < 0.001) as compared to the saline + PCP-treated group.
Fig. 2 Overall effects of cariprazine and aripiprazole on the attenuation of
the PCP-induced increase in Glu levels expressed as the relative AUC(0–
180 min) values of the drug-treated groups and compared to the saline +
PCP group. Compared to the saline + PCP-treated group, relative AUC(0–
180 min) values were significantly lower for the saline + saline-treated
group (★★★, P < 0.001), for the cariprazine 0.2 mg/kg + saline-treated
group ( , P < 0.001), for all three cariprazine doses (✡✡✡, ✠✠✠,
✚✚✚, P < 0.001), and for the aripiprazole-treated group at 20 mg/kg
(✞✞✞, P < 0.001) but not at 3 mg/kg
Fig. 3 Effects of cariprazine and aripiprazole on the PCP-induced
increase in extracellular levels of DA in the mPFC of awake rats. a
PCP significantly increased the DA levels as compared to the saline +
saline-treated group (hexagons; ★★, P < 0.01; ★★★, P < 0.001) and
cariprazine 0.2 mg/kg + saline-treated group (triangles down; ,
P < 0.01; , P < 0.001). Cariprazine significantly attenuated
PCP-induced DA release at 0.05 mg/kg (squares; ✡✡✡, P < 0.001),
0.2 mg/kg (triangles up; ✠, P < 0.05; ✠✠, P < 0.01; ✠✠✠, P < 0.001),
and 0.8 mg/kg (diamonds;✚, P < 0.05;✚✚✚, P < 0.001). bAripiprazole
significantly attenuated PCP-induced DA release at 3 mg/kg (triangles;
, P < 0.05; , P < 0.001) and 20 mg/kg (diamonds; ✞✞, P < 0.01;
✞✞✞, P < 0.001). c Compared to the saline + PCP-treated group, relative
AUC(0–180 min) values were significantly attenuated for the saline + saline-
treated group (★★★, P < 0.001), for the cariprazine 0.2 mg/kg + saline-
treated group ( , P < 0.001), for all three cariprazine doses (✡,
P < 0.05; ✠✠✠,✚✚✚, P < 0.001), and for the aripiprazole-treated group at
20 mg/kg (✞✞✞, P < 0.001)
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Both higher cariprazine doses caused similar effects, as al-
ready illustrated for Glu and DA.
The extracellular levels of 5-HT in the rat mPFC were also
increased following the systemic administration of PCP, but to
a lesser extent, than did those of DA and NA. The maximal
increase, to 201 ± 30% (P < 0.001) of the control 5-HT levels,
was achieved at 30 min (Fig. 5a). Pretreatment with
cariprazine at all three doses significantly attenuated the
PCP-induced 5-HT release in the 30-min (P < 0.001) and
60-min (P < 0.01 and P < 0.001) fractions, and the highest
dose completely abolished the PCP effect on 5-HT release
observed during the first 90 min after PCP injection.
Cariprazine (0.2 mg/kg) administered alone had no effects
on the basal 5-HT levels. Pretreatment with aripiprazole at
both tested doses significantly (P < 0.01 for 3 mg/kg and
P < 0.001 for 20 mg/kg) attenuated the PCP-induced 5-HT
release starting at 30min after the PCP injection (Fig. 5b). The
statistical analysis results and the corresponding F and P
values are listed in Table 2. The overall effects of cariprazine
and aripiprazole on the attenuation of the PCP-induced in-
crease in 5-HT levels, expressed as the relative AUC(0–
180 min) values of the drug-treated groups and compared to
the saline + PCP group, are shown in Fig. 5c. The AUC(0–
180 min) values were significantly lower only for the highest
doses of cariprazine (P < 0.01) and aripiprazole (P < 0.001).
Effects of cariprazine and aripiprazole administered
in combination with PCP on locomotor activity of rats
Administration of PCP caused a rapid increase in the locomo-
tor activity of rats undergoing microdialysis sampling,
reaching the maximal value of 78.3 ± 24.4 counts/5 min at
20 min (Fig. 6a). The PCP-induced increase was markedly
higher andmore prolonged than the increases in motor activity
caused by the handling stress and the stress caused by the oral
Fig. 4 Effects of cariprazine and aripiprazole on the PCP-induced
increase in extracellular levels of NA in the mPFC of awake rats. a
PCP significantly increased the NA levels as compared to the saline +
saline-treated group (hexagons; ★★★, P < 0.001) and cariprazine
0.2 mg/kg + saline-treated group (triangles down; , P < 0.001).
Cariprazine significantly attenuated PCP-induced NA release at
0.05 mg/kg (squares; ✡, P < 0.05; ✡✡✡, P < 0.001), 0.2 mg/kg
(triangles up; ✠✠, P < 0.01; ✠✠✠, P < 0.001), and 0.8 mg/kg (diamonds;
✚✚✚, P < 0.001). b Aripiprazole significantly attenuated PCP-induced
NA release at 3 mg/kg (triangles; , P < 0.05; , P < 0.01; ,
P < 0.001) and 20 mg/kg (diamonds; ✞✞, P < 0.01; ✞✞✞, P < 0.001). c
Compared to the saline + PCP-treated group, relative AUC(0–180 min)
values were significantly attenuated for the saline + saline-treated group
(★★★, P < 0.001), for the cariprazine 0.2 mg/kg + saline-treated group
( , P < 0.001), for all three cariprazine doses (✡, P < 0.05, ✠✠✠,
✚✚✚, P < 0.001), and for both aripiprazole-treated groups, 3 mg/kg ( ,
P < 0.05) and 20 mg/kg (✞✞✞, P < 0.001)
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administration of saline or the test compounds at time −
60 min and saline at 0 min. Pretreatment with cariprazine
significantly (P < 0.001) attenuated the PCP-induced motor
activation during the period from 15 to 25 min post PCP
injection for all three doses. The highest dose completely
abolished (P < 0.001) the PCP-induced locomotion for an
additional 10-min period (the 15–35-min period post PCP
injection) (Fig. 6a). Similar effects were observed for
aripiprazole administered at doses of 3 and 20 mg/kg
(Fig. 6b). The statistical analysis results using two-way repeat-
ed measures ANOVA followed by Bonferroni’s post test and
the corresponding F and P values are listed in Table 2. The
overall effects of cariprazine and aripiprazole on the attenua-
tion of the PCP-induced increase in locomotor activity during
the entire sampling period of 180 min and compared to the
corresponding value of the saline + PCP group are shown in
Fig. 6c. The values were significantly lower only for the
highest doses of cariprazine (P < 0.01) and aripiprazole
(P < 0.01).
Discussion
The results of the present microdialysis study show that acute
oral treatment with cariprazine dose-dependently attenuated
the PCP-induced increases in the extracellular levels of Glu,
DA, NA, and 5-HT in the mPFC. Cariprazine alone (tested
only as 0.2 mg/kg) had no effect on Glu, DA, NA, and 5-HT
levels or motor activity. Cariprazine at oral doses of 0.05, 0.2,
and 0.8 mg/kg attenuated the increase in locomotor activity
induced by PCP in rats undergoing microdialysis sampling;
this effect was only statistically significant at the 0.8 mg/kg
dose. PCP caused only a modest, non-significant decrease in
GABA levels; therefore, a clear tendency of cariprazine and
aripiprazole to reverse this effect could not be statistically
confirmed. Similar observations were made for aripiprazole,
Fig. 5 Effects of cariprazine and aripiprazole on the PCP-induced
increase in extracellular levels of 5-HT in the mPFC of awake rats. a
PCP significantly increased the 5-HT levels as compared to the saline +
saline-treated group (hexagons; ★, P < 0.05; ★★★, P < 0.001) and
cariprazine 0.2 mg/kg + saline-treated group (triangles down; ,
P < 0.01; , P < 0.001). Cariprazine significantly attenuated
PCP-induced 5-HT release at 0.05 mg/kg (squares; ✡✡✡, P < 0.001),
0.2 mg/kg (triangles up; ✠✠, P < 0.01; ✠✠✠, P < 0.001), and 0.8 mg/kg
(diamonds; ✚✚✚, P < 0.001). b Aripiprazole significantly attenuated
PCP-induced DA release at 3 mg/kg (triangles; , P < 0.01) and
20 mg/kg (diamonds; ✞, P < 0.05; ✞✞✞, P < 0.001). c Compared to the
saline + PCP-treated group, relative AUC(0–180 min) values were
significantly attenuated for the saline + saline-treated group (★★,
P < 0.01), for the cariprazine 0.2 mg/kg + saline-treated group
( , P < 0.001), and for the highest doses of cariprazine (✚✚,
P < 0.01) and aripiprazole (✞✞✞, P < 0.001)
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Fig. 6 Effects of cariprazine and aripiprazole on PCP-induced increase of
locomotor activity in rats undergoing microdialysis sampling. a
Cariprazine significantly attenuated the peak of PCP-induced locomotor
activation during the 15–35-min period for the 0.8 mg/kg dose
(P < 0.001) and the 20–25-min period for the 0.05 and 0.2 mg/kg doses
(P < 0.001). b Aripiprazole significantly attenuated the PCP-induced
locomotor activation during the 15–25-min period for the 3 mg/kg dose
(P < 0.001) and the 15–35-min period for the 20 mg/kg dose (P < 0.001).
c PCP significantly increased the locomotor activity of rats as compared
to the saline + saline-treated group (★, P < 0.05) and cariprazine
0.2 mg/kg + saline-treated group ( , P < 0.05). Compared to the saline
+ PCP-treated group, cariprazine at 0.8 mg/kg (✚✚, P < 0.01) and
aripiprazole at 20 mg/kg (✞✞, P < 0.01) significantly attenuated the total
motor activity, expressed in counts/180 min
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which was chosen as a reference substance and evaluated at
doses of 3 and 20 mg/kg, p.o., in separate groups of rats.
In analogy to the use of PCP rodent models to evaluate
antipsychotic drugs in behavioral tests, microdialysis can pro-
vide a mechanistic insight into the in vivo changes in neuro-
transmitter signaling and the role of the respective receptors
and circuits involved.
The initial studies explored the role of the metabotropic Glu
receptors (mGluRs) in modulating Glu release in the rat mPFC.
The increase in Glu efflux and locomotor activation and stereo-
typy induced by PCPwere abolished in rats that were pretreated
with themGluR II agonist LY354740, whereas the DA levels in
the mPFC and nucleus accumbens remained increased
(Moghaddam and Adams 1998). In the following study, the
same authors concluded that clozapine, haloperidol, and the
5-HT2A receptor antagonist M100907 did not effectively block
the PCP-induced Glu release (Adams and Moghaddam 2001).
M100907 was not found to be active during clinical trials in
schizophrenia, suggesting a critical role for other neurotransmit-
ters and their receptors in the pharmacological profile of current
antipsychotic drugs (Ebdrup et al. 2011). NRA0045, a potent
D4, 5-HT2A, and α1 adrenoceptor antagonist, inhibited the
PCP-induced Glu release in the rat mPFC (Abekawa et al.
2003). Likewise, single administration of clozapine attenuated
PCP-induced Glu release and hyperlocomotion at both 30-min
(Abekawa et al. 2006) and 48-h (Abekawa et al. 2007) periods
before PCP injection. In the following study, rats were chroni-
cally treated with PCP, and chronic clozapine treatment signif-
icantly attenuated both the PCP-induced increase in cortical Glu
efflux and the reduction in GABA markers parvalbumin and
GAD67 (Amitai et al. 2012).
In addition, local infusion of PCP decreased the GABA
levels in the rat PFC (Yonezawa et al. 1998), and both sys-
temic and local PCP potently inhibited the potassium-
stimulated GABA release in the rat striatum (Hondo et al.
1995). In our study, we observed a modest, insignificant de-
crease in basal extracellular GABA concentrations following
systemic PCP challenge.
The importance of the afferent inputs to the PFC and their
role in the systemic effects of the NMDA receptor antagonists
cannot be excluded. This is of particular significance when
considering the NMDA receptor antagonist-induced disinhibi-
tion of the glutamatergic outputs from the mPFC neurons.
Thus, local infusion of ketamine via a microdialysis probe in
the mPFC did not increase Glu but did increase DA levels,
whereas local infusion of NMDA increased Glu while decreas-
ing DA release (Lorrain et al. 2003). Likewise, local perfusion
of the AMPA receptor antagonist LY293558 through a probe
placed in the ventral tegmental area (VTA) inhibited the PCP-
induced locomotor activation and cortical, but not accumbal,
DA release (Takahata and Moghaddam 2003).
The major finding in our study is that both cariprazine and
aripiprazole dose-dependently attenuated the PCP-induced
Glu efflux in the rat mPFC, similar to the prototype atypical
antipsychotic drug clozapine (Abekawa et al. 2006; Amitai
et al. 2012). The highest doses of cariprazine (0.8 mg/kg)
and aripiprazole (20 mg/kg) almost completely abolished the
PCP-induced effects on Glu and 5-HT levels and the locomo-
tor activity of rats undergoing microdialysis sampling.
However, oral aripiprazole was previously shown to have no
effect on basal Glu levels in the rat mPFC (Carli et al. 2011).
The DA and NA levels were also significantly and dose-
dependently attenuated but remained increased between 136
and 157% of the basal levels even after the highest doses of
cariprazine and aripiprazole. Previous studies have shown that
aripiprazole at a low dose (0.3 mg/kg) increased DA levels,
and higher doses had no effect in either rats (Li et al. 2004) or
mice (Zocchi et al. 2005). The effect of cariprazine and
aripiprazole on PCP-induced 5-HTefflux is in agreement with
the study of Amargos-Bosch et al. (2003) showing that cloza-
pine and olanzapine, but not haloperidol, suppressed the 5-HT
efflux elicited by PCP or ketamine in the mPFC of rats. This
study, together with the NRA0045 antagonist data (Abekawa
et al. 2003), supports the hypothesis that the blockade of the 5-
HT2A receptors and α1 adrenoceptors by atypical antipsychot-
ic drugs may contribute to the blockade of the PCP-induced
increase in cortical 5-HT and Glu efflux. PCP-induced stimu-
lation of the AMPA receptors could be attenuated by the local
perfusion of the AMPA receptor antagonist LY293558
through probes in both the PFC and VTA (Takahata and
Moghaddam 2003). Stimulation of the mPFC with local infu-
sion of S-AMPAwas reversed by 5-HT2A receptor antagonists
(Amargos-Bosch et al. 2003), providing a functional link be-
tween the NMDA, AMPA, and 5-HT2A receptors, i.e., be-
tween the efflux of Glu and 5-HT elicited by PCP.
Cariprazine and aripiprazole have similar binding affinities
to the rat 5-HT2A and 5-HT1A receptors, whereas cariprazine
is about 10 times less potent than aripiprazole at the human 5-
HT2A receptors (Kiss et al. 2010). However, both cariprazine
and aripiprazole are more potent antagonists at the 5-HT2A
receptors than clozapine, which may account for their robust
effect on PCP-induced Glu and 5-HT release, and locomotor
activity. The effects of cariprazine and aripiprazole on PCP-
induced locomotor activity may not be due to a non-specific
attenuation of spontaneous activity producing catalepsy and/
or sedation as our previous findings showed no effect of these
compounds on these parameters (Gyertyán et al. 2011).
Clozapine was shown to at tenuate PCP-induced
hyperlocomotion, but only partially (Abekawa et al. 2006).
There was a shift in the time course profiles of DA release
in the mPFC and in the locomotor activity of rats following
systemic PCP administration (Adams andMoghaddam 1998).
Our results are in line with this observation, showing the
markedly delayed and sustained increases in Glu, DA, NA,
and 5-HT levels compared to the locomotor activity. PCP
induced the maximal increase in forward locomotion between
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20 and 25 min post injection, whereas the peak effects for the
monoamines occurred at 60 min for DA and NA and 30 min
for 5-HT. One possible limitation of the study is the difference
in the temporal resolution of the behavioral recordings,
counting the activity in 5-min bins, and the microdialysis
sampling in 30-min intervals. Regardless of the differences
in time intervals for monitoring the behavioral and neuro-
chemical endpoints, these findings indicate that PCP-
induced locomotor activation precedes the elevation of Glu
levels in the mPFC. The prolonged increase in DA efflux is
not capable of sustaining the locomotion, as reported else-
where (Adams and Moghaddam 1998).
In conclusion, both cariprazine and aripiprazole dose-
relatedly attenuated PCP-induced hyperlocomotion and
acute increases in Glu, DA, NA, and 5-HT levels in the
mPFC, with cariprazine displaying a much greater poten-
cy than aripiprazole. The potency of cariprazine was ap-
proximately fivefold higher than that of aripiprazole when
comparing the doses of 0.2 mg/kg cariprazine and 3 mg/
kg aripiprazole corrected for their bioavailability. The bio-
availability of cariprazine and aripiprazole in rat is 53%
(Gyertyán et al. 2011) and 16% (EMA/737723/2013), re-
spectively, which correspond to effective doses of 0.106
and 0.48 mg/kg, respectively. As acute PCP (or ketamine)
has been proven to model the psychotic, cognitive, and
negative symptoms of schizophrenia, cariprazine may
have benefits for improving cognitive deficits and nega-
tive symptoms of schizophrenia in addition to being an
effective antipsychotic agent. Interestingly, recent clinical
results demonstrated the increased efficacy of cariprazine
over risperidone in patients with predominant negative
symptoms (Németh et al. 2017). Future studies are needed
to explore the role of cariprazine’s unique receptor profile,
including D3 receptor activity, in the treatment of negative
symptoms and cognitive deficits of schizophrenia.
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